Last updated: February 25, 2026
What is the Drug Corresponding to NDC 51407-0251?
NDC 51407-0251 corresponds to Eylea (aflibercept), a vascular endothelial growth factor (VEGF) inhibitor used primarily to treat various retinal conditions, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular disorders.
Market Landscape for Eylea (Aflibercept)
Market Size and Growth
The global ophthalmic drugs market, driven significantly by anti-VEGF therapies, is projected to expand at a compound annual growth rate (CAGR) of approximately 5.8% between 2021 and 2028.[1]
- 2022 Global Market Value: Estimated at $16.4 billion.
- Leading Indications for Eylea:
- Wet AMD accounts for 45% of anti-VEGF prescriptions worldwide.
- DME accounts for approximately 25%.
- Other uses include retinal vein occlusion and myopic choroidal neovascularization.[2]
Competitive Landscape
Eylea competes primarily with Ranibizumab (Lucentis) and Bevacizumab (Avastin).
| Drug |
Market Share (2022) |
Indications |
Pricing (per dose) |
Approved in Countries |
| Eylea |
45% |
AMD, DME, RVO, CNV |
~$2,100 |
US, EU, Japan |
| Lucentis |
35% |
AMD, DME, RVO |
~$2,000 |
US, EU, Japan |
| Avastin |
15% |
Off-label for ocular use |
~$50 |
US, EU (off-label) |
Market penetration depends on indications, pricing, and reimbursement policies.
Regulatory Status
Eylea is approved by the FDA for:
- Wet AMD
- DME
- RVO (branch and central)
In the EU, approved for similar indications. Japan and other markets follow similar approvals.
Price Trends and Projections
Historical Pricing
- 2019-2022: The average price per dose has remained stable, around $2,000 to $2,200.
- Pricing Factors: Manufacturing costs, patent protections, reimbursement rates.
Influences on Future Pricing
- Biosimilar Competition: Entry anticipated around 2024-2026 could pressure prices downward.
- Market Penetration: Expansion into emerging markets may lead to volume growth but at lower prices.
- Reimbursement Policies: Changes to healthcare policies, especially in the US, could influence net prices.
- Innovative Delivery: Longer-acting formulations may reduce injection frequency, impacting pricing strategies.
Price Projections (2023-2028)
| Year |
Estimated Average Price Per Dose |
Notes |
| 2023 |
~$2,100 |
Stable, with minor adjustments for inflation |
| 2024 |
~$2,050 |
Slight decline expected with biosimilar launch |
| 2025 |
~$2,000 |
Biosimilar market gains, reimbursement pressure |
| 2026 |
~$1,950 |
Shift towards value-based pricing |
| 2027 |
~$1,900 |
Increased biosimilar presence, margin compression |
| 2028 |
~$1,850 |
Possible stabilization or further reduction |
Market Risks and Opportunities
Risks
- Patent Expiry: Biosimilar entry likely by 2024–2026.
- Pricing Pressure: Reimbursement reforms may limit price growth.
- Market Saturation: Limited scope for growth in mature markets.
Opportunities
- Emerging Markets: Expansion into Asia, Latin America.
- New Indications: Approval for additional retinal or ocular diseases.
- Delivery Innovations: Longer-lasting formulations could reduce treatment frequency, impacting pricing.
Summary of Key Data Points
- Global ophthalmic anti-VEGF market: $16.4 billion (2022).
- Market share: Eylea holds approximately 45%.
- Pricing: Around $2,100 per injection in 2023.
- Projected price decline: Entry of biosimilars expected to reduce prices by 5–10% annually post-2024.
- Market growth drivers: Chronic disease prevalence, aging populations, unmet needs in emerging markets.
Key Takeaways
- Eylea is a leading anti-VEGF therapy with stable pricing and significant market share.
- Biosimilar competition is expected to start impacting pricing from 2024.
- Market expansion in emerging regions offers growth potential despite pricing pressures.
- Longer-acting formulations may influence future revenue, either positively through better adherence or negatively by reducing injection frequency.
- Reimbursement and regulatory policies will remain critical determinants of net pricing and market access.
FAQs
-
What are the primary competitors to Eylea in the market?
Lucentis and Avastin are the main competitors, with biosimilars emerging as additional pressure points.
-
When are biosimilars expected to enter the Eylea market?
Likely between 2024 and 2026, based on patent expiration and regulatory pathways.
-
How will biosimilar entry affect the price of Eylea?
Prices could decrease by 5-10% annually post-entry, with sensitive pricing depending on market acceptance.
-
Are there upcoming formulations that could impact Eylea’s market?
Longer-acting formulations are in development, aiming to reduce injection frequency, potentially altering market dynamics.
-
What are growth opportunities outside developed markets?
Expanding into Asia, Latin America, and Africa is feasible due to rising prevalence of retinal diseases and increasing healthcare infrastructure.
References
[1] MarketsandMarkets. (2022). Ophthalmic Drugs Market by Application, Distribution Channel, and Region.
[2] IQVIA. (2022). Global Ophthalmology Market Data and Trends.
